Rapid power, precise control: the evolving role of intravenous P2Y12 inhibition in chronic coronary syndromes, acute coronary syndromes, and cardiogenic shock (ESC 2026) - Jul 1, 2026 - Pres time: Aug 28, 2026; 10:00 AM - 10:45 AM; Location: Beirut (Hall A3); Online; "Sponsored by Chiesi Farmaceutici SpA To analyse the pharmacological rationale in acute coronary syndromes: evaluate the impact of delayed oral P2Y12 absorption in STEMI and NSTE-ACS patients and assess how the rapid onset of intravenous inhibition mitigates peri-procedural thrombotic risk (transition schemes); To optimise outcomes in chronic coronary syndromes: identify high-risk clinical and anatomical subsets within the chronic coronary syndromes population that derive the greatest benefit from the reversible, precise platelet inhibition offered by cangrelor during elective PCI; and To navigate the critical care gap: evaluate the evidence for cangrelor as a feasible alternative to oral P2Y12 inhibitors in cardiogenic shock, focusing on its ability to bypass impaired gastrointestinal absorption and provide reliable platelet inhibition in haemodynamically unstable patients"
Acute Coronary Syndrome • Cardiovascular
|